Navigation Links
Best way to treat malaria: Avoid using same drug for everyone, scientists say

A team of scientists employing a sophisticated computer model pioneered at Princeton University and Resources for the Future has found that many governments worldwide are recommending the wrong kind of malaria treatment.

Despite the availability of many drugs and therapies to treat malaria, many countries' national policies recommend using what is known as a single first-line therapy -- that is, using one drug repeatedly with many patients. Writing in the Sept. 16 issue of the Proceedings of the National Academy of Sciences, a team led by Maciej Boni, who conducted the research as a postdoctoral fellow at Princeton and scholar at Resources, a Washington, D.C.-based think tank, reports that countries could cut the death rate and forestall the development of drug resistance if a variety of different drugs were distributed to patients.

This approach, known as multiple first-line therapies or MFT, could be put into place by making sure different drugs cost about the same, so that patients would not be forced into buying the cheapest available drug but would choose from a random pool. Or it could be applied by clinic physicians who could simply alternate their choices for drugs they prescribe to patients.

"What we found is that using multiple first-line therapies is the best way to avoid treatment failures and to delay the development of resistance for as long as possible," said Boni, who recently has joined the staff of the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam.

One catch to the researchers' strategy is that multiple effective therapies may not always be available. In some African countries where drug-resistance is already widespread, the only effective therapies are a class of drugs known as artemisinin-based combination therapies (ACTs).

"MFT does not necessarily solve all our problems," said Boni. "Antimalarial drug development needs to continue with the hope of producing novel and highly effective antimalarials that can be deployed alongside ACTs."

Some 350 to 500 million people are infected with malaria every year by being bitten by a mosquito carrying one of the four human malaria parasites, P. falciparum, P. vivax, P. malaria or P. ovale, according to statistics maintained by the World Health Organization. Falciparum infections are by far the most common, killing more than 1 million people each year. Malaria also contributes indirectly to many more deaths, mainly in young children, among those already suffering from other infections and illnesses. About 60 percent of the cases of malaria worldwide and more than 80 percent of malaria deaths occur in sub-Saharan Africa.

Boni, a mathematician as well as an evolutionary biologist, and his co-authors, Ramanan Laxminarayan and David Smith, designed a computer model with inputs based on more than 100 years of malaria field research. They simulated dozens of treatment paths for a malaria outbreak among patients contrasting many variations of the status quo strategy of using a single first-line therapy with one employing MFT.

They found there were major benefits to employing an MFT strategy, namely, fewer cases of malaria, fewer unsuccessful drug treatments, and a very significant delay in the onset of drug resistance in the parasites. As parasite resistance to antimalarial drugs is the key factor that can make drugs obsolete and useless, delaying and slowing down the evolution of drug-resistance is often viewed as a public health priority when designing strategies for eliminating or controlling malaria.

The computerized analysis conducted by the team represents the most extensive look yet at the question of what works best for large-scale and long-term malaria control. Boni, whose research focuses on the public health consequences of the evolution of infectious diseases, said their study was largely influenced by the work of the theoretical ecologist Simon Levin. Levin, the George M. Moffett Professor of Biology at Princeton, has over the past four decades pioneered techniques that apply rigorous mathematical analysis to biological problems, paving the way for work such as this, according to Boni.


Contact: Kitta MacPherson
Princeton University

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. A new radiation therapy treatment developed for head and neck cancer patients
3. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
4. Gamma globulin effective in treating eye infections caused by adenoviruses
5. Presence of gene mutation helps guide thyroid cancer treatment
6. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
7. New genetic research into nicotine addiction shows promise for personalized treatment
8. Doctors learn to control their own brains pain responses to better treat patients
9. Interleukin-8, key marker for colorectal cancer treatment
10. New class of drug offers hope to treatment-resistant AIDS patients
11. Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer
Post Your Comments:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology: